Objective: Many patients with metastatic colorectal cancer (MCRC) cannot afford the targeted
therapy in China. There is no standard treatment when these patients whose tumors relapsed following
the first- and second- line chemotherapy. The goal of the present study is to evaluate the efficacy
and safety of continuous intravenous infusion (CIV) of low-dose 5-fluorouracil5-FUfor
heavily pretreated patients with MCRC. Methods: Twenty-three heavily pretreated patients with
MCRC received 5-FU 200 mg/m2 per day as CIV for more than 30 days. Efficacy and safety was
evaluated after one cycle of chemotherapy. Results: No patient achieved complete response (CR), 2 patients partial response
(PR), 8 patients stable disease (SD), and 13 patients progression disease (PD). Response rate (RR) was 8.7%, disease
control rateCR+PR+SD was 43.5%Toxicity was mild. Conclusion: This study showed that continuous venous
infusion of low-dose 5-fluorouracil was moderately active and well tolerated in heavily pretreated patients with MCRC.
Keywords: Low-dose 5-fluorouracil, continuous intravenous infusion, metastatic colorectal cancer.
Rights & PermissionsPrintExport